Study on the correlation between pulmonary ground-glass nodules and Helicobacter pylori infection

doi:10.3877/cma.j.issn.2095-2015.2024.03.015

Abstract

Abstract:

Objective

To investigate the relationship between pulmonary ground-glass nodule (GGN) and Helicobacter pylori (Hp) infection in the physical examination population in Shanghai area.

Methods

A total of 42318 subjects were included who underwent lung CT examination and ¹³C urea breath test (UBT) at the health examination center of Huadong Hospital Affiliated to Fudan University from January 2021 to December 2021. The subjects were divided into GGN and non-GGN groups, the differences of tumor markers and Hp positive rate between the two groups were analyzed using independent sample t test, Mann-Whitney U test and Chi-squared test. The association between GGN and Hp positive was analyzed by Logistic regression.

Results

The proportion of GGN positive subjects was higher in females than in males (20.67% vs. 14.43%), and the Hp positive rate was higher in males than in females (26.89% vs. 20.66%). The Hp positive rate in the GGN group was lower than that in the non-GGN group (22.33% vs. 24.15%). The differences were all statistically significant. The age, NSE, CA199, AFP were significantly higher in the GGN group than those in the non-GGN group. The male proportion, body mass index, white blood cell, hemoglobin, squamous cell carcinoma antigen and carcinoembryonic antigen were significantly lower in the GGN group than those in the non-GGN group. Logistic regression analysis also showed a significantly negative correlation between GGN and Hp positive after adjusting for confounding factors (OR=0.863, P<0.001).

Conclusion

The formation of GGN is associated with many risk factors, and Hp infection may have a protective effect on the occurrence of GGN.

Key words: Pulmonary ground-glass nodule, Helicobacter pylori, Infection, Negative correlation

Jian Zou, Jianhua Cong, Yue Tian, Minkun Huang, Ting Sun, Zhiqin Wang, Lihua Shen, Zhenhui Gao. Study on the correlation between pulmonary ground-glass nodules and Helicobacter pylori infection[J]. Chinese Journal of Digestion and Medical Imageology(Electronic Edition), 2024, 14(03): 258-262.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhxhbyyxzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.2095-2015.2024.03.015

https://zhxhbyyxzz.cma-cmc.com.cn/EN/Y2024/V14/I03/258

Figures/Tables 2

References 36

[1]	Oudkerk M, Liu S, Heuvelmans MA, et al. Lung cancer LDCT screening and mortality reduction-evidence, pitfalls and future perspectives[J]. Nat Rev Clin Oncol, 2021, 18(3): 135-151.
[2]	Hyuna S, Jacques F, Rebecca LS, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2021, 71(3): 209-249.
[3]	Kakinuma R, Noguchi M, Ashizawa K, et al. Natural history of pulmonary subsolid nodules: a prospective multicenter study[J]. J Thorac Oncol, 2016, 11(7): 1012-1028.
[4]	Lee HW, Jin KN, Lee JK, et al. Long-term follow-up of ground-grass nodules after 5 years of stability[J]. J Thorac Oncol, 2019, 14(8): 1370-1377.
[5]	Dai J, Yu G, Yu J. Can CT imaging features of ground-glass ocpacity predict invasiveness? A meta-analysis[J]. Thoracic Cancer, 2018, 9(4): 452-458.
[6]	Pellicano R, Ianiro G, Fagoonee S, et al. Review: Extragastric diseases and Helicobacter pylori[J]. Helicobacter, 2020, 25(Suppl 1): e12741.
[7]	Buzás GM. Helicobacter pylori and non-alcoholic fatty liver disease[J]. Minerva Gastroenterol Dietol, 2020, 66: 267-279.
[8]	Zuo ZT, Ma Y, Sun Y, et al. The protective effects of Helicobacter pylori infection on allergic asthma[J]. Int Arch Allergy Immunol, 2021, 182: 53-64.
[9]	Doulberis M, Papaefthymiou A, Polyzos SA, et al. Association between active Helicobacter pylori infection and glaucoma: A systematic review and meta-analysis[J]. Microorganisms, 2020, 8: 894.
[10]	Doulberis M, Kotronis G, Gialamprinou D, et al. Alzheimer’s disease and gastrointestinal microbiota; impact of Helicobacter pylori infection involvement[J]. Int J Neurosci, 2021, 131: 289-301.
[11]	Mounika P. Helicobacter pylori infection and risk of lung cancer: A meta-analysis[J]. Lung Cancer Int, 2013, 2013: 131869.
[12]	中华医学会呼吸病学分会肺癌学组, 中国肺癌防治联盟专家组. 肺结节诊治中国专家共识(2018年版)[J]. 中华结核和呼吸杂志, 2018, 41(10): 763-771.
[13]	Chen Y, Segers S, Blaser MJ. Association between Helicobacter pylori and mortality in the NHANES Ⅲ study[J]. Gut, 2013, 62(9): 1262-1269.
[14]	Philippou N, Koursarakos P, Anastasakou E, et al. Helicobacter pylori seroprevalence in patients with lung cancer[J]. World J Gastroenterol, 2004, 10(22): 3342-3344.
[15]	Najafizadeh K, Falah Tafti S, Shiehmorteza M, et al. H pylori seroprevalence in patients with lung cancer[J]. World J Gastroenterol, 2007, 13(16): 2349-2351.
[16]	Koshiol J, Flores R, Lam TK, et al. Helicobacter pylori seropositivity and risk of lung cancer[J]. PLoS One, 2012, 7(2): e32106.
[17]	Sun S, Schiller J, Gazdar A. Lung cancer in never smokers-a different disease[J]. Nat Rev Cancer, 2007, 7(10): 778-790.
[18]	Shi Z, Deng J, She Y, et al. Quantitative features can predict further growth of persistent pure ground-glass nodule[J]. Quant Imaging Med Surg, 2019, 9(2): 283-291.
[19]	Ece F, F Hatabay N, Erdal N, et al. Does Helicobacter pylori infection play a role in lung cancer?[J]. Respir Med, 2005, 99(10): 1258-1262.
[20]	Gocyk W, Niklifiski T, Olechnowicz H, et al. Helicobacter pylori, gastrin and cyclooxygenase-2 in lung cancer[J]. Med Sci Monit, 2000, 6(6): 1085-1092.
[21]	Behroozian R, Moradkhan E. The assessment of probable relationship between lung cancer and Helicobacter pylori infection[J]. Trop Gastroenterol, 2010, 31(1): 34-36.
[22]	Janssen-Heijnen ML, Coebergh JW. The changing epidemiology of lung cancer in Europe[J]. Lung Cancer, 2003, 41: 245-258.
[23]	Sugimoto M, Uotani T, Ichikawa H, et al. Gastroesophageal reflux disease in time covering eradication for all patients infected with Helicobacter pylori in Japan[J]. Digestion, 2016, 93(1): 24-31.
[24]	孔洋洋, 刘立新. 胃食管反流病患者幽门螺杆菌感染率的Meta分析[J/OL]. 中华消化病与影像杂志(电子版), 2017, 7(5): 205-210.
[25]	Ravelli AM, Panarotto MB, Verdoni L, et al. Pulmonary aspiration shown by scintigraphy in gastroesophageal reflux-related respiratory disease[J]. Chest, 2006, 130(5): 1520-1526.
[26]	Kim J, Lee JH, Kim Y, et al. Association between chronic obstructive pulmonary disease and gastroesophageal reflux disease: a national cross-sectional cohort study[J]. BMC Pulm Med, 2013, 13: 51.
[27]	Ates F, Vaezi MF. Insight into the relationship between gastroesophageal reflux disease and asthma[J]. Gastroenterol Hepatol (NY), 2014, 10(11): 729-736.
[28]	Lee JS, Collard HR, Anstrom KJ, et al. Anti-acid treatment and disease progression in idiopathic pulmonary fibrosis: an analysis of data from three randomised controlled trials[J]. Lancet Respir Med, 2013, 1(5): 369-376.
[29]	Linz B, Balloux F, Moodley Y, et al. An African origin for the intimate association between human and Helicobacter pylori[J]. Nature, 2007, 445: 915-918.
[30]	Kayhan B, Arasli M, Eren H, et al. Analysis of peripheral blood lymphocyte phenotypes and Th1/Th2 cytokines profile in the systemic immune responses of Helicobacter pylori infected individuals[J]. Microbiol Immunol, 2008, 52: 531-538.
[31]	Nakashima S, Kakugawa T, Yura H, et al. Identification of Helicobacter pylori VacA in human lung and its effects on lung cells[J]. Biochem Biophys Res Commun, 2015, 460(3): 721-726.
[32]	Altobelli A, Bauer M, Velez K, et al. Helicobacter pylori VacA targets myeloid cells in the gastric lamina propria to promote peripherally induced regulatory T-cell differentiation and persistent infection[J]. mBio, 2019, 10(2): e00261-219.
[33]	Gebert B, Fischer W, Weiss E, et al. Helicobacter pylori vacuolating cytotoxin inhibits T lymphocyte activation[J]. Science, 2003, 301: 1099-1102.
[34]	Luther J, Owyang SY, Takeuchi T, et al. Helicobacter pylori DNA decreases pro-inflammatory cytokine production by dendritic cells and attenuates dextran sodium sulphate-induced colitis[J]. Gut, 2011, 60(11): 1479-1486.
[35]	Duramad O, Fearon KL, Chang B, et al. Inhibitors of TLR-9 act on multiple cell subsets in mouse and man in vitro and prevent death in vivo from systemic inflammation[J]. J Immunol, 2005, 174: 5193-5200.
[36]	Samareh-Fekri M, Hashemi Bajgani SM, Shafahi A, et al. Detection of Helicobacter pylori in the bronchoalveolar lavage of patients with lung cancer using real-time PCR[J]. Jundishapur J Microbiol, 2016, 9(11): e32144.

组别	例数	年龄[岁,M(Q1,Q3)]	性别[男性例数(%)]	BMI(kg/m²,±s)	WBC(10⁹/L,±s)	Hb(g/L,±s)	NSE(μg/L,±s)
结节组	3976	43.00(36.00,54.00)	1756(44.20%)	23.87±3.39	6.33±1.51	144.73±15.93	13.30±3.90
无结节组	18698	42.00(35.00,53.00)	10224(54.70%)	24.22±3.48	6.40±1.52	147.26±15.82	13.15±3.77
t/χ²/Z值		-5.29	145.47	5.96	2.67	9.17	-2.07
P值		<0.001	<0.001	<0.001	0.008	<0.001	0.039
组别	例数	CY21-1[μg/L,M(Q1,Q3)]	SCC[μg/L,M(Q1,Q3)]	CA199[ku/L,M(Q1,Q3)]	CEA[μg/L,M(Q1,Q3)]	AFP[μg/L,M(Q1,Q3)]	CA724[μg/L,M(Q1,Q3)]	Hp阳性[例(%)]
结节组	3976	2.13(1.63,2.85)	0.30(0.21,0.47)	8.11(5.32,12.63)	1.77(1.24,2.52)	4.05(3.19,5.24)	2.10(1.16,4.44)	864(21.73)
无结节组	18698	2.15(1.63,2.89)	0.31(0.21,0.48)	7.85(5.07,12.15)	1.80(1.24,2.59)	3.99(3.12,5.13)	2.16(1.16,4.42)	4373(23.39)
t/χ²/Z值		-0.69	-2.64	-3.35	-2.01	-3.39	-0.72	5.07
P值		0.485	0.008	<0.001	0.045	<0.001	0.471	0.024

组别	例数	年龄[岁,M(Q1,Q3)]	性别[男性例数(%)]	BMI(kg/m²,±s)	WBC(10⁹/L,±s)	Hb(g/L,±s)	NSE(μg/L,±s)
结节组	3976	43.00(36.00,54.00)	1756(44.20%)	23.87±3.39	6.33±1.51	144.73±15.93	13.30±3.90
无结节组	18698	42.00(35.00,53.00)	10224(54.70%)	24.22±3.48	6.40±1.52	147.26±15.82	13.15±3.77
t/χ²/Z值		-5.29	145.47	5.96	2.67	9.17	-2.07
P值		<0.001	<0.001	<0.001	0.008	<0.001	0.039
组别	例数	CY21-1[μg/L,M(Q1,Q3)]	SCC[μg/L,M(Q1,Q3)]	CA199[ku/L,M(Q1,Q3)]	CEA[μg/L,M(Q1,Q3)]	AFP[μg/L,M(Q1,Q3)]	CA724[μg/L,M(Q1,Q3)]	Hp阳性[例(%)]
结节组	3976	2.13(1.63,2.85)	0.30(0.21,0.47)	8.11(5.32,12.63)	1.77(1.24,2.52)	4.05(3.19,5.24)	2.10(1.16,4.44)	864(21.73)
无结节组	18698	2.15(1.63,2.89)	0.31(0.21,0.48)	7.85(5.07,12.15)	1.80(1.24,2.59)	3.99(3.12,5.13)	2.16(1.16,4.42)	4373(23.39)
t/χ²/Z值		-0.69	-2.64	-3.35	-2.01	-3.39	-0.72	5.07
P值		0.485	0.008	<0.001	0.045	<0.001	0.471	0.024

项目	模型一[OR值(95% CI)]	模型二[OR值(95% CI)]
Hp	0.814^*(0.745~0.889)	0.863^*(0.789~0.945)
性别		0.510^*(0.471~0.553)
年龄(18~30岁=1)
31~45岁		1.922^*(1.660~2.225)
46~60岁		2.339^*(2.005~2.727)
>60岁		2.393^*(2.021~2.834)
BMI		0.971^*(0.959~0.982)
NSE		1.030^*(1.020~1.040)
AFP		1.056^*(1.035~1.077)

项目	模型一[OR值(95% CI)]	模型二[OR值(95% CI)]
Hp	0.814^*(0.745~0.889)	0.863^*(0.789~0.945)
性别		0.510^*(0.471~0.553)
年龄(18~30岁=1)
31~45岁		1.922^*(1.660~2.225)
46~60岁		2.339^*(2.005~2.727)
>60岁		2.393^*(2.021~2.834)
BMI		0.971^*(0.959~0.982)
NSE		1.030^*(1.020~1.040)
AFP		1.056^*(1.035~1.077)

Please choose a citation manager

Content to export